Last reviewed · How we verify
Apomivir®
Apomivir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.
Apomivir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication. Used for HIV-1 infection (in combination antiretroviral therapy).
At a glance
| Generic name | Apomivir® |
|---|---|
| Also known as | FE-L-APO(drug substance) |
| Sponsor | Far East Bio-Tec Co., Ltd |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The drug inhibits HIV protease, an essential enzyme required for the cleavage of viral polyproteins into functional components. By blocking this enzyme, Apomivir prevents the production of infectious viral particles, thereby reducing viral load in HIV-infected patients. This mechanism is typical of protease inhibitor antiretrovirals used in combination antiretroviral therapy.
Approved indications
- HIV-1 infection (in combination antiretroviral therapy)
Common side effects
- Gastrointestinal disturbances
- Lipid abnormalities
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apomivir® CI brief — competitive landscape report
- Apomivir® updates RSS · CI watch RSS
- Far East Bio-Tec Co., Ltd portfolio CI